Partnerships

Partnering to advance precision cancer immunotherapy.

MIORG engages with pharma, biotech, diagnostic organizations, academic groups, hospitals, and translational research partners looking to strengthen biomarker strategy, resistance biology, or combination development in immuno-oncology.

Partner profile

Science-driven organizations seeking disciplined oncology collaboration with practical translational value.

Collaboration areas

How MIORG can engage.

Pharma and biotech collaboration

Program strategy, biomarker framing, and translational support for immuno-oncology assets.

Diagnostic partnerships

Co-development or validation dialogue around predictive immune profiling and companion diagnostic tools.

Clinical collaborations

Clinically grounded biomarker work, cohort interpretation, and translational planning.

Academic collaborations

Joint research discussions around immune resistance, antigen presentation, and dendritic cell biology.

Investor and funding dialogue

Conversations around strategic financing, translational milestones, and non-dilutive funding opportunities.

Translational immunology consulting

Targeted scientific consulting for biomarker, tumor immunology, and combination design questions.

Contact

Open to focused partnership conversations.

MIORG welcomes outreach from organizations interested in predictive oncology, combination immunotherapy, and translational cancer immunology collaboration.